Evaluating risk stratification and sepsis-related mortality in patients with positive blood cultures via procalcitonin combined with the PIRO system in the ED.
Aim
Prolactinoma, a prolactin (PRL) secreting functioning pituitary tumor, is the most common of all pituitary adenomas (PA) accounting for 40-60% and dopamine agonists (DA) are the cornerstone of treatment. The aim of this study was to review the clinical presentation, treatment modalities and therapeutic outcomes of patients with prolactinomas in the South Asia region.
Methods
This retrospective study was conducted in the Endocrinology Department of Shaukat Khanum Memorial Cancer Hospital and Research Centre from December 2011 till December 2019. Medical records were used to retrieve for patient’s demographics, clinical features at diagnosis, PRL levels and size of prolactinoma on MRI at diagnosis and after start of dopamine agonists and outcome of medical management.
Results
A total of 107 patients were included in this study. Mean age at diagnosis was 35 (22-54) years for men and 32 (18-50) years for women and 66.4% (71) of the patients were females. Our study incl
FOx BIOSYSTEMS , a company on the mission to revolutionize life science and pharmacological research with innovative real-time, analysis products and the Biosensors research group at KU Leuven, focused on developing innovative bio-molecular detection concepts and miniaturized analysis systems, announced a novel, label-free assay that can characterize the polyclonal antibody response against